Antasol Injection

Adult dosage

Generally, 500 mL is administered as an intravenous infusion. The infusion rate is usually set at 180 minutes or more for 500 mL in adults. When administered via central venous injection, 500 mL of this medication should be mixed with glucose solution and continuously infused into the central vein over 24 hours. Adjustments should be made according to age, symptoms, and body weight.

This medication must be used under the direction of a physician. It should not be administered to patients with severe renal dysfunction or elevated nitrogen levels in the blood, and patients with metabolic disturbances in amino acid metabolism in addition to liver dysfunction. Additionally, patients with metabolic disorders that inhibit nitrogen utilization, severe heart failure or pulmonary edema, and patients with little or no urine output should not use this medication. Patients with elevated sodium and chloride levels in the blood or alkalosis, those with excessive body fluids, and those with a history of myocardial infarction should also refrain from administering this medication. Patients with severe acidosis, congestive heart failure, severe heart failure, or edema due to sodium retention should be administered this medication with caution. This medication contains sodium bisulfite, which can cause serious allergic reactions or asthma attacks in patients allergic to sulfites or those with asthma, so caution is necessary. Rarely, hypersensitivity reactions such as skin rashes may occur when administering this medication, and it should be discontinued immediately if such symptoms appear. Gastrointestinal symptoms such as nausea or vomiting, chest discomfort, palpitations, rapid pulse, and elevated blood pressure may also occur. Rapid large dose administration can result in acidosis and may lead to serious side effects such as chills, fever, headache, respiratory distress or respiratory arrest, shock, bronchospasm, and urinary tract spasms. Metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, hypoglycemia, elevated liver enzymes, vitamin imbalances, electrolyte disturbances, and hyperammonemia in children may occur. Patients with liver or kidney dysfunction may have elevated nitrogen levels in the blood, and severely impaired liver function may result in blood amino acid imbalance and metabolic alkalosis, along with consciousness disturbances. Caution with electrolyte balance is necessary when administering large doses or using other medications that contain electrolytes, as overdose may cause metabolic alkalosis. In patients with renal disease, pulmonary disease, or severe heart disease, careful administration is needed to prevent excessive accumulation of body fluids. Diabetic patients should monitor their blood glucose levels frequently while using this medication, and patients with hyponatremia or liver or kidney dysfunction must have their dosage adjusted and manage their fluids and electrolytes meticulously. This medication can reduce the protein-sparing effect of amino acids when used with tetracycline antibiotics. The safety for pregnant women has not been established, and it should only be administered when the benefits of treatment outweigh the risks. Children typically have immature liver function, so it is advisable to maintain lower concentrations; particularly in infants, as they may lack the ability to synthesize urea leading to hyperammonemia, so blood ammonia levels should be monitored frequently. Elderly patients may have diminished physical function, thus requiring careful monitoring of administration speed and dosage reduction. This medication contains electrolytes, so caution should be taken regarding electrolyte balance during large doses or when used with other electrolyte-containing medications. Infusions should be administered slowly intravenously, as rapid injections can lead to chills or vomiting and significant loss of amino acids through the kidneys. In cold temperatures, warming the medication to body temperature for administration is advisable. Due to the risk of infection during administration, it is crucial to maintain a sterile environment while preparing or handling the drug and ensure the sterilization of injection equipment. If the solution is cloudy or discolored, or if there are droplets on the packaging, it should not be used, and it should be used promptly after opening and within 24 hours if refrigerated. If crystals form, it should be heated to about 50-60 degrees to dissolve, then cooled to body temperature for use. When storing, soft bag products do not require vent holes, and vial products should have the patient entrance punctured just before administration to prevent leakage of the solution. If the solution is discolored or has leaked, or if the packaging film has been peeled off, it must not be used, and accurate dosage should be used as per the scale on the container.

Serious side effects

Hives, shortness of breath, respiratory arrest, shock, bronchospasm, asthma attacks, severe systemic swelling (edema) accompanied by elevated blood pressure, liver failure and kidney failure, liver abnormalities (potentially related to jaundice), myocardial infarction and related symptoms, severe allergic reactions, significant edema or urinary abnormalities

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• rapid pulse (tachycardia)
• elevated blood pressure
• metabolic acidosis
• hypophosphatemia
• alkalosis

This medication should be stored in a sealed container to prevent air or moisture from entering. It should be kept away from direct sunlight and stored at normal room temperature.

Appearance

A colorless, transparent solution in a glass vial with a rubber stopper for infusion.

Package unit

250 milliliters/vial x 1